In NSCLC and hepatocellular carcinoma (HCC), the inhibition of PD-1 on tumor CD103+CD8+ T cells stimulated with anti-CD3 plus anti-CD28 antibodies enhances IFN-γ production by these cells (115, 125) (Table 2). Here, CD28 is linked to hepatocellular carcinoma.